Skylar Jeremias

January 05, 2023

Celltrion Healthcare submitted a biologics license application (BLA) to the FDA for its biobetter of its infliximab biosimilar allowing for subcutaneous administration (Remsima SC).

January 03, 2023

Health Canada has approved the high-concentration version of Samsung Bioepis and Organon’s Hadlima, a citrate-free adalimumab biosimilar referencing Humira.

January 02, 2023

Biosimilar news in ophthalmology throughout the year tended to focus on the advancements of ranibizumab biosimilars, such as the US launch of Byooviz, the recall of a biobetter of ranibizumab, and the UK approval of Ongavia.

January 01, 2023

To say goodbye to 2022 and welcome in the new year, The Center for Biosimilars recaps the biggest news stories and milestones from the past 12 months as well as list of the top 5 podcast episodes of the year.

December 30, 2022

Conferences throughout 2022 shared new information on white bagging, the safety of biosimilar substitution, the use of a biobetter, and discussion around the role that pharmacy benefit managers play in biosimilar adoption.

December 29, 2022

News surrounding biosimilars referencing Humira (adalimumab) topped the list of biosimilar articles related to rheumatology in 2022, highlighting the excitement for these biosimilars to launch starting in early 2023.

December 28, 2022

Ian Henshaw, senior vice president and global head of biosimilars at Biogen, shares his thoughts on whether clinical efficacy and switching studies to establish biosimilar safety are necessary, a hotly debated topic in the biosimilars industry.

December 27, 2022

The American Journal of Managed Care, a sister site of The Center for Biosimilars, looked back at some of the most popular biosimilars content of 2022 to be published on AJMC.com.

December 26, 2022

The top 5 most-read articles about oncology within the biosimilars industry involved a number of FDA approvals and new data on the market impact of biosimilar competition on Roche’s blockbuster reference products.

December 25, 2022

John Gabrielson, senior vice president at JSR Life Sciences and head of Similis Bio, shares his perspective on how clinical efficacy testing and recent actions from the Biden Administration, such as the executive order on biotechnology investment, impact biosimilar development.